| Objective:To observe the effectiveness and adverse drug reactions of three pharmacotherapeutic schemes for rheumatoid arthritis. Their results were then analyzed and evaluated with the pharmacoeconomic method. Method:Sixty-nine patients were randomly divided into three groups, Scheme A(25 patients):Sulfasalazine + Methotrexate + Meloxicam; Scheme B(23 patients): Hydroxychloroquine + Methotrexate + Meloxicam; Scheme C(21 patients): Leflunomid + Methotrexate + Meloxicam. Result:After 12 weeks'treatment, the effective rates of schemes A, B, C were 76% , 73.91% and 80.95% , and the costs were 789.13, 1712.45 and 2138.73 yuan, respectively. After 24 weeks treatment, the effective rates of schemes A,B,C were 84% , 86.96% and 90. 48% , and the costs were 1249.27, 3066.51 and 4010. 07 yuan, respectively. Conclusion:The effectiveness and adverse drug reactions of the three schemes had no significant difference (P>0.05), Scheme A had the lowest cost (P<0.01).From a pharmacoeconomic point of view, its cost is superior to the others. |
